Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer

Enzyme and Protein

Volumn 49, Issue 1-3, 1996, Pages 85-93

  Duffy, M J ^a   Duggan, C ^a   Maguire, T ^a   Mulcahy, K ^a   Elvin, P ^a   McDermott, E ^a   Fennelly, J J ^a   O'Higgins, N ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Breast cancer; ELISA; mRNA; Prognosis; Urokinase plasminogen activator

Indexed keywords

CATHEPSIN B; CATHEPSIN D; MESSENGER RNA; RECEPTOR; UROKINASE;

ARTICLE; BREAST CANCER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREDICTION; PROGNOSIS;

EID: 0029942299     PISSN: 10196773     EISSN: None     Source Type: Journal    
DOI: 10.1159/000468618     Document Type: Article

References (34)

1. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985;44:139-266.
2. Duffy MJ: Urokinase plasminogen activator and malignancy. Fibrinolysis 1993;7:295-302.
3. Dano K, Behrendt N, Brunner N, Ellis V, Plough M, Pyke C: The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 1994;8(suppl.l):189-203.
4. Vassalli J-D: The urokinase receptor. Fibrinolysis 1994;8(suppl 1):172-181.
5. Ho C, Wilhelm SM, Pentland AP, Marmer BL, Grant GA, Eisen AZ, Goldberg GT: Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sei USA 1989:86:2632-2636.
6. Odekon LE, Blasi F, Rifkin DB: Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-β to TGF-β. J Cell Physiol 1994:158:398-407.
7. Gold LI, Schwimmer R, Ouigley JP: Human plasma fibronectin as a substrate for human urokinase. Biochem J 1989:262:529-534.
8. Mars K, Zarnegar R, Michalopoulos GK: Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am J Pathol 1993:143:949-958.
9. Fazioli F, Blasi F: Urokinase-type plasminogen activator and its receptor: New targets for anti-metastatic therapy. Trends Pharmacol Sei 1994;15:25-29.
10. Bugge TH, Suh TT, Flick MJ, Daugherty CC, Romers J, Solberg H, Ellis V, Dano K, Degen JL: The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J Biol Chem 1995:270:16886-16894.
11. Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly JJ, Duffy MJ: Urokinase plasminogen activator and urokinase plasminogen receptor in breast cancer. Int J Cancer 1995;61:597-600.
12. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidium thiocyanate-phenol chloroform extraction. Anal Biochem 1987;162:156-159.
13. Duffy MJ, O'Siorain L, Waldron B, Smith C: Estradiol receptors in human breast carcinomas assayed by use of monoclonal antibodies. Clin Chem 1986:32:1972-1974.
14. Duffy MJ, Blaser J, Duggan C, McDermott E, O'Higgins N, Fennelly JJ, Tschesche H: Assay of matrix metalloproteases types 8 and 9 by ELISA in human breast cancer. Br J Cancer 1995:71:1025-1028.
15. Salsela O, Rifkin DB: Release of basic fibroblast growth factor-heperan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J Cell Biol 1990;110:767-775.
16. Baillie CT, Winslet MC, Bradley NJ: Tumour vasculature - (a) potential therapeutic target. Br J Cancer 1995;72:257-267.
17. Weidner N. Semple JP. Welch WR, Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;32:l-8.
18. Pepper MS, Belin D, Montesano R, Orci L, Vassalli J-D: Transforming growth factor-beta-1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. J Cell Biol 1990;! 11:743-755.
19. Reith A, Rucklidge GJ: Invasion of brain tissue by primary glioma: Evidence for the involvement of urokinase-type plasminogen activator as an activator of type IV collagenase. Biochem Biophys Res Commun 1992:186:348-354.
20. Binder BR: Influence of urokinase on cell proliferaton and invasion. Blood Coagul Fibrinolysis 1990:1: 717-720.
21. He C-J, Rebibou J-M, Peraldi M-N, Meulders Q, Rondeau E: Growth factor-like effect of urokinase-type plasminogen activator in human renal cells. Biochem Biophys Res Commun 1991:176:1408-1416.
22. Anichini E, Fibbi G. Pucci M, Caldini R, Chevanne M, Del Rosso M: Production of second messenger following chemotactic and mitogenic urokinase-receptor interaction in human fibroblasts and mouse fibroblasts transfected with human urokinase receptor. Exp Cell Res 1994:213:438448.
23. Boros P, Miller CM: Hepatocyte growth factor: (a) multifunctional cytokine. Lancet 1995:354:293-295.
24. Rabbani SA, Mazar AP, Bernier SM, Haq M, Bolivar I, Henkin J, Goltzman D: Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J Biol Chem 1992:267:14151-14156.
25. Ossowski L, Ouigley JP, Reich E: Plasminogen, a necessary factor for cell migration in vitro, in Reich E. Rifkin DB, Shaw E, (eds): Proteases and Biological Control. Cold Spring Harbor/NY. Cold Spring Harbor Laboratory, 1975, pp 901-903.
26. Busso N. Masur SK, Lazega D, Waxman S, Ossowski L: Induction of cell migration by prourokinase binding to its receptor: Possible mechanism for signal transduction in human epithelial cells. J Cell Biol 1994:126: 259-270.
27. Waltz DA, Sailor LZ, Chapman HA: Cytokines induce urokinase-dependent adhesion of human myeloid cells. J Clin Invest 1993:91:1541-1552.
28. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ. Andreasen P: Urokinase plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990:50:6827-6829.
29. Janicke F, Schmitt M, Hafter R, Holrieder A, Babic R, Ulm K. Gossner W, Graeff H: Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 1990:4:69-78.
30. Janicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H, Graeff H: Urokinase plasminogen activator and its inhibitor PAI-1 are strong and independent prognostic factor in node-negative breast cancer. Breast Cancer Res Treat 1993:24:195-208.
31. Foekens JS, Schmitt M, Pache L, van Putton W, Peters HA, Bontenbal M, Janicke F, Klijn JGM: Prognostic values of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992;52: 6101-6105.
32. Duffy MJ, Reilly D, McDermott E, O'Higgins N, Fennelly JJ, Andreasen PA: Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer 1994:4:2276-2280.
33. Duffy MJ: Proteases as prognostic markers in cancer. Clin Cancer Res, in press.
34. Foekens JA, Look MP, Peters HA, van Putten W, Portengen H, Klijn JGM: Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 1995:87:751-756.